Sexual Health and Breast Cancer: Developing Appropriate Education for Women Going Through Treatment

Sponsor
University of Colorado, Denver (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06121258
Collaborator
(none)
50
1
9

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the acceptability, appropriateness, and feasibility of a educational video series for patients going through breast cancer treatment.

Condition or Disease Intervention/Treatment Phase
  • Other: Educational video series
N/A

Detailed Description

This is a prospective, mixed methods pilot study to evaluate the acceptability, appropriateness, and feasibility of a novel educational video series for patients going through breast cancer treatment. The video series addresses topics such as what to expect from breast surgery, how to prepare for breast surgery, treatment effects of breast cancer therapies, and mitigation and communication strategies for navigating breast cancer treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Sexual Health and Breast Cancer: Developing Appropriate Education for Women Going Through Treatment
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Video website access

Participants will gain access to the educational video website in order to watch the series.

Other: Educational video series
The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.

Outcome Measures

Primary Outcome Measures

  1. Acceptability of the educational video series after six-months of access and use by breast cancer patients as measured by AIM instrument. [6 months]

    The Acceptability of Intervention Measure (AIM) is a validated instrument used to measure the acceptability of an intervention. Scores range from 0-5. There is no score cut off, however higher scores indicate better outcomes (greater acceptability).

  2. Appropriateness of the educational video series after six-months of access and use by breast cancer patients as measured by IAM instrument. [6 months]

    The Intervention Appropriateness Measure (IAM) is a validated instrument used to measure the appropriateness of an intervention. Scores range from 0-5. There is no score cut off, however higher scores indicate better outcomes (greater appropriateness).

  3. Determine the sustainability of the educational video series after six-months of access and use by breast cancer patients as measured by the FIM instrument. [6 months]

    The Feasibility of Intervention Measure (FIM) is a validated instrument used to measure the feasibility, or sustainability, of an intervention. Scores range from 0-5. There is no score cut off, however higher scores indicate better outcomes (greater feasibility).

Secondary Outcome Measures

  1. Change from baseline in sexual health and function at six-months, as measured by the PROMIS Sexual Function v2 Brief Profile (Female) [Baseline, 6 months]

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function v2 Brief Profile (Female) is a well-validated tool in oncology patients to assess sexual health. Calibrated subdomain scores are expressed as T-scores (mean=50, standard deviation=10). A T-score 50 corresponds to the mean response among cancer survivors used for previous item testing. Higher scores indicate better outcomes within the domain. We will assess the change at 6 months from baseline.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Stage I-III invasive breast cancer within one month of initial multi-disciplinary clinic visit or surgical consultation

  • Ability to complete survey material independently

  • Able to read and speak English

  • Willingness to comply with study material and procedures

Exclusion Criteria:
  • Age < 18 years old

  • Stage 0 or IV breast cancer

  • Non-breast cancer diagnoses

  • History of anti-hormonal therapy, chemotherapy, or radiotherapy not related to breast cancer

  • Prior breast cancer diagnosis

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Colorado, Denver

Investigators

  • Principal Investigator: Sarah E Tevis, MD, University of Colorado, Denver

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT06121258
Other Study ID Numbers:
  • 23-1734.cc
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Colorado, Denver
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023